4-((4-phenylpiperazin-1-yl)methyl)aniline | 40224-23-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-((4-phenylpiperazin-1-yl)methyl)aniline
• 英文别名: 1-phenyl-4-[(4-aminophenyl)methyl]piperazine；4-[(4-Phenylpiperazin-1-YL)methyl]aniline
• CAS: 40224-23-5
• 化学式: C₁₇H₂₁N₃
• mdl: MFCD09702730
• 分子量: 267.374
• InChiKey: HFSSYCWTIGVIPL-UHFFFAOYSA-N

物化性质

• 沸点：
  431.3±40.0 °C(Predicted)
• 密度：
  1.145±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-((4-phenylpiperazin-1-yl)methyl)aniline 在 镍 吡啶 、 盐酸 、 硫酸 、 硝酸 、 一水合肼 作用下， 以 乙醇 、 二氯甲烷 、 乙酸酐 、 1,2-二氯乙烷 为溶剂， 反应 29.0h， 生成 4-[(4-Phenylpiperazin-1-yl)methyl]benzene-1,2-diamine
  参考文献：
  名称：

  Roglic; Dukic-Stefanovic; Andric, Pharmazie, 2001, vol. 56, # 10, p. 803 - 807

  摘要：

  DOI：
• 作为产物：
  描述：

  对硝基溴化苄 在 铁粉 、 氯化铵 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 4.0h， 生成 4-((4-phenylpiperazin-1-yl)methyl)aniline
  参考文献：
  名称：

  Development of a potent and selective FLT3 kinase inhibitor by systematic expansion of a non-selective fragment-screening hit

  摘要：

  A non-selective inhibitor (1) of FMS-like tyrosine kinase-3 (FLT3) was identified by fragment screening and systematically modified to afford a potent and selective inhibitor 26. We confirmed that 26 inhibited the growth of FLT-3-activated human acute myeloid leukemia cell line MV4-11. Our design strategy enabled rapid development of a novel type of FLT3 inhibitor from the hit fragment in the absence of target-structural information. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.03.006

文献信息

• [EN] NOVEL POTASSIUM CHANNEL BLOCKER<br/>[FR] NOUVEAU BLOQUANT DU CANAL POTASSIQUE
  申请人：XENTION LTD

  公开号：WO2010023445A1

  公开（公告）日：2010-03-04

  The present invention provides a compound of formula (I):or its salts or pharmaceutically acceptable derivatives wherein; R1 is selected from the group consisting of optionally substituted arylalkyl, optionally substituted aryl, optionally substituted heteroarylalkyl and optionally substituted heteroaryl; R2 is selected from the group consisting of optionally substituted acyl, optionally substituted sulfonyl and optionally substituted sulfamoyl; R3 is selected from the group consisting of hydrogen, halogen, hydroxyl, alkoxy, aryloxy, optionally substituted alkyl, optionally substituted amino, optionally substituted amino carbonyl, optionally substituted amino sulfonyl or nitrile; X1 is selected from a group consisting of a chemical bond, CR7R8, C(=O), C(=NH), NR9, NHC(O), and SO2 wherein; R7 and R8 are independently selected from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl and optionally substituted heteroaryl or; R7 and R8 together form an optionally substituted C4-6 cycloalkyl ring; R9 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aryl and optionally substituted heteroaryl; A represents an optionally substituted saturated or partially saturated 4-7 membered ring with the general formula (A): or is selected from formula (B): For each occurrence; X2 is CH or N; X3 is CH2, CH(R5a), C(R5a)(R5b), NH, N(R5c), O or S; X4 is independently selected from C(=O), CH2, CH(R4a) or C(R4a)(R4b); R4a and R4b for each occurrence is independently halogen, optionally substituted amino, hydroxyl, optionally substituted alkoxy, optionally substituted aryloxy, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted aryl or optionally substituted heteroaryl; R5a and R5b for each occurrence is independently, halogen, optionally substituted amino, hydroxyl, optionally substituted alkoxy, optionally substituted aryloxy, optionally substituted alkyl, optionally substituted alkanoyl, optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted aryl or optionally substituted heteroaryl; R5c is optionally substituted acyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted aryl or optionally substituted heteroaryl; n = 1 or 2. The compounds are useful as potassium ion channel inhibitors.

  本发明提供了一种化合物，其化学式为(I)：或其盐或药学上可接受的衍生物，其中；R1选自可选择地取代的芳基烷基，可选择地取代的芳基，可选择地取代的杂芳基烷基和可选择地取代的杂芳基；R2选自可选择地取代的酰基，可选择地取代的磺酰基和可选择地取代的磺胺基；R3选自氢、卤素、羟基、烷氧基、芳氧基、可选择地取代的烷基、可选择地取代的氨基、可选择地取代的氨基羰基、可选择地取代的氨基磺酰基或腈的群；X1选自化学键、CR7R8、C(=O)、C(=NH)、NR9、NHC(O)和SO2的群，其中；R7和R8各自选自氢、可选择地取代的烷基、可选择地取代的环烷基、可选择地取代的芳基和可选择地取代的杂芳基或；R7和R8一起形成一个可选择地取代的C4-6环烷基环；R9选自氢、可选择地取代的烷基、可选择地取代的芳基和可选择地取代的杂芳基；A代表一个可选择地取代的饱和或部分饱和的4-7成员环，其一般式为(A)：或选自式(B)：对于每次出现；X2为CH或N；X3为CH2、CH(R5a)、C(R5a)(R5b)、NH、N(R5c)、O或S；X4独立地选自C(=O)、CH2、CH(R4a)或C(R4a)(R4b)；R4a和R4b每次出现时独立地为卤素、可选择地取代的氨基、羟基、可选择地取代的烷氧基、可选择地取代的芳氧基、可选择地取代的烷基、可选择地取代的环烷基、可选择地取代的芳基烷基、可选择地取代的芳基或可选择地取代的杂芳基；R5a和R5b每次出现时独立地为卤素、可选择地取代的氨基、羟基、可选择地取代的烷氧基、可选择地取代的芳氧基、可选择地取代的烷基、可选择地取代的烷酰基、可选择地取代的环烷基、可选择地取代的芳基烷基、可选择地取代的芳基或可选择地取代的杂芳基；R5c为可选择地取代的酰基、可选择地取代的烷基、可选择地取代的环烷基、可选择地取代的芳基烷基、可选择地取代的芳基或可选择地取代的杂芳基；n = 1或2。这些化合物可用作钾离子通道抑制剂。
• N-phenyl-imidazolidine-1-ones
  申请人：Boehringer Ingelheim GmbH

  公开号：US03937708A1

  公开（公告）日：1976-02-10

  Compounds of the formula ##SPC1## Wherein R is hydrogen, halogen, lower alkyl or lower alkoxy, R' is --CHR.sub.1 --Q--A, --CHR.sub.2 --A or --O--CHR.sub.2 --CHR.sub.1 --Q--A, each in m- or p-position, Where A is ##SPC2## Q is straight or branched alkylene of 1 to 4 carbon atoms, R.sub.1 is hydrogen, hydroxyl, lower alkoxy or --O--CO--R.sub.5, R.sub.2 is hydrogen or methyl, R.sub.3 and R.sub.4, which may be identical to or different from each other, are each hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl or, together with each other and neighboring carbon atoms of the phenyl ring to which they are attached, form a saturated or unsaturated carbocyclic 5- to 6-membered ring, R.sub.5 is lower alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, amino, (mono-lower alkyl)-amino or (di-lower alkyl)-amino, Z is an aromatic heterocyclic ring with one to two heteroatoms, which may optionally be condensed with a benzene ring, and R" is hydrogen, straight or branched lower alkyl, lower alkenyl, lower alkynyl, hydroxy-lower alkyl, (di-lower alkyl)-amino-lower alkyl or aralkyl, And their non-toxic, pharmacologically acceptable acid addition salts; the compounds as well as their salts are useful as CNS-depressants, neuroleptics, analgesics, antiphlogistics, spasmolytics, broncholytics, hypotensives and anti-cholesteremics.

  式为##SPC1##的化合物，其中R为氢、卤素、较低的烷基或较低的烷氧基，R'为--CHR.sub.1 --Q--A、--CHR.sub.2 --A或--O--CHR.sub.2 --CHR.sub.1 --Q--A，每个在m-或p-位置，其中A为##SPC2##，Q为1至4个碳原子的直链或支链烷基，R.sub.1为氢、羟基、较低的烷氧基或--O--CO--R.sub.5，R.sub.2为氢或甲基，R.sub.3和R.sub.4，它们可以相同也可以不同，每个为氢、较低的烷基、较低的烷氧基、卤素、三氟甲基或与它们相邻的苯环碳原子一起形成饱和或不饱和的碳环5至6元环，R.sub.5为较低的烷基、卤代较低的烷基、羟基较低的烷基、较低的烷氧基较低的烷基、氨基、(单较低的烷基)-氨基或(二较低的烷基)-氨基，Z为含有一到两个杂原子的芳香杂环，可以选择性地与苯环融合，R"为氢、直链或支链较低的烷基、较低的烯基、较低的炔基、羟基较低的烷基、(二较低的烷基)-氨基较低的烷基或芳基烷基，以及它们的无毒、药理学上可接受的酸盐；这些化合物及其盐可用作中枢神经系统抑制剂、神经阻滞剂、镇痛剂、抗炎药、解痉药、支气管扩张剂、降压药和抗胆固醇药。
• [EN] ARYLALKYLPIPERAZINES FOR USE AS NEUROPROTECTIVE AGENTS<br/>[FR] ARYLALKYLPIPÉRAZINES DESTINÉES À ÊTRE UTILISÉES EN TANT QU'AGENTS NEUROPROTECTEURS
  申请人：UNIV HERTFORDSHIRE HIGHER EDUCATION CORP

  公开号：WO2016051155A1

  公开（公告）日：2016-04-07

  A compound of the general formula A or a or a pharmaceutically acceptable salt or solvate thereof, wherein: R1 is selected from the group consisting of: C1-C12-alkyl, C3-C12-cycloalkyl, C6- C10-aryl, and C5-C7-heteroaryl; each optionally substituted with halogen, hydroxyl, OCOR3, amino, C1-C6-alkylamino, C1-C6-dialkylamino, C1C6- (halo)alkyl, C1C6-(halo)- alkoxy and/or COOR3; R2 is selected from the group consisting of: C6-C10-aryl and C5-C7-heteroaryl; each optionally substituted with halogen, hydroxyl, OCOR3 amino, C1C6- alkylamino, CrC6-dialkyl- amino, C1-C6-(halo)alkyl, C1C6-(halo)alkoxy and/or COOR3; R3 is independently at each occurrence selected from the group consisting of hydrogen and C1-C2-alkyl; and n is an integer from 1 to 10 inclusive.

  通式A或其药学上可接受的盐或溶剂的化合物，其中：R1选自以下组合中的一种：C1-C12-烷基，C3-C12-环烷基，C6-C10-芳基和C5-C7-杂芳基；每种均可选择性地取代卤素、羟基、OCOR3、氨基、C1-C6-烷基氨基、C1-C6-二烷基氨基、C1C6-(卤)烷基、C1C6-(卤)烷氧基和/或COOR3；R2选自以下组合中的一种：C6-C10-芳基和C5-C7-杂芳基；每种均可选择性地取代卤素、羟基、OCOR3氨基、C1C6-烷基氨基、CrC6-二烷基氨基、C1-C6-(卤)烷基、C1C6-(卤)烷氧基和/或COOR3；R3在每次出现时独立地选自氢和C1-C2-烷基组合；n为1到10之间的整数（包括1和10）。
• [DE] IN 6-STELLUNG SUBSTITUIERTE INDOLINONE, IHRE HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL<br/>[EN] 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT<br/>[FR] INDOLINONES SUBSTITUEES EN POSITION 6, LEUR PREPARATION ET LEUR UTILISATION EN TANT QUE MEDICAMENTS
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2001027081A1

  公开（公告）日：2001-04-19

  Die vorliegende Erfindung betrifft in 6-Stellung substituierte Indolinone der allgemeinen Formel (I), in der R1 bis R5 und X wie im Anspruch 1 definiert sind, deren Isomere und deren Salze, insbesondere deren physiologisch verträgliche Salze, welche Wertvolle pharmakologische Eigenschaften aufweisen, insbesondere eine inhibierende Wirkung auf verschiedene Rezeptor-Tyrosinkinasen und Cyclin/CDK-Komplexe sowie auf die Proliferation von Endothelzellen und verschiedener Tumorzellen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung.

  本发明涉及一般式（I）中R1至R5和X如权利要求1所定义的6-位取代的吲哚酮及其异构体和盐，特别是其生理上可接受的盐，具有有价值的药理学特性，特别是对各种受体酪氨酸激酶和环/ CDK复合物以及内皮细胞和各种肿瘤细胞的增殖具有抑制作用，含有这些化合物的药物，其使用和制备方法。
• Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
  申请人：Heckel Armin

  公开号：US20060194813A1

  公开（公告）日：2006-08-31

  The present invention relates to indolinone derivatives substituted in the 6 position of general formula wherein R 1 to R 6 and X are defined as in claim 1 , the tautomers, enantiomers, diastereomers, mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof, which have valuable pharmacological properties, in particular an inhibiting effect on various receptor tyrosine kinases and on the proliferation of endothelial cells and various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

  本发明涉及一种在通式中6位取代的吲哚酮衍生物，其中R1至R6和X如权利要求1所定义，其互变异构体、对映异构体、顺反异构体、混合物及其盐，特别是其生理上可接受的盐，具有有价值的药理特性，特别是对各种受体酪氨酸激酶和内皮细胞以及各种肿瘤细胞的增殖具有抑制作用，包含这些化合物的制药组合物，它们的用途和制备过程。